Published in Cardiol Res Pract on January 02, 2012
Level of unawareness and management of diabetes, hypertension, and dyslipidemia among adults in Luxembourg: findings from ORISCAV-LUX study. PLoS One (2013) 0.95
Blood pressure control in hypertensive patients in the "Hiperdia Program": a territory-based study. Arq Bras Cardiol (2014) 0.94
Hypertension-related knowledge, practice and drug adherence among inpatients of a hospital in samarkand, uzbekistan. Nagoya J Med Sci (2014) 0.77
Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet (2006) 37.83
Global burden of hypertension: analysis of worldwide data. Lancet (2005) 32.76
Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet (2009) 26.09
2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens (2003) 11.32
Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation (1992) 4.96
Inflammation, hypertension, and the metabolic syndrome. JAMA (2003) 2.57
Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. J Am Coll Surg (2008) 2.19
Intra-abdominal obesity: an untreated risk factor for Type 2 diabetes and cardiovascular disease. J Endocrinol Invest (2006) 1.62
Nonalcoholic steatosis and steatohepatitis IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. Am J Physiol Gastrointest Liver Physiol (2002) 1.40
Relation of the "hypertriglyceridemic waist" phenotype to earlier manifestations of coronary artery disease in patients with glucose intolerance and type 2 diabetes mellitus. Am J Cardiol (2006) 1.23
A global perspective on blood pressure treatment and control in a referred cohort of hypertensive patients. J Clin Hypertens (Greenwich) (2010) 1.18
Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study. J Hum Hypertens (2007) 1.14
Effect of cardiometabolic risk factors on hypertension management: a cross-sectional study among 28 physician practices in the United States. Cardiovasc Diabetol (2010) 1.02
Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardiometabolic Risk Profile in Patients with hypertension disease survey. J Hypertens (2008) 1.00
Blood glucose and coronary artery disease in nondiabetic patients. Diabetes Care (2006) 1.00
Inter-regional comparisons of the prevalence of cardiometabolic risk factors in patients with hypertension in Europe: the GOOD survey. J Hum Hypertens (2008) 0.96
Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the i-SEARCH global study. J Hypertens (2007) 0.94
Differences in healthy lifestyle characteristics between adults with prehypertension and normal blood pressure. J Hypertens (2009) 0.94
Blood pressure control and components of the metabolic syndrome: the GOOD survey. Cardiovasc Diabetol (2009) 0.91
Influence of atorvastatin on blood pressure control in treated hypertensive, normolipemic patients - An open, pilot study. Blood Press (2010) 0.87
Where are we with the management of hypertension? From science to clinical practice. J Clin Hypertens (Greenwich) (2009) 0.81
JAMA patient page. The metabolic syndrome. JAMA (2006) 0.80
Blood pressure-lowering response to amlodipine as a determinant of the antioxidative activity of small, dense HDL3. Am J Cardiovasc Drugs (2011) 0.78
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. Ann Intern Med (2015) 4.62
Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk. Arch Intern Med (2010) 3.15
High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species. Circulation (2003) 2.44
Differential roles of GSK-3β during myocardial ischemia and ischemia/reperfusion. Circ Res (2011) 2.10
Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. J Am Coll Cardiol (2006) 1.98
Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J (2013) 1.90
Selective inhibition of protein kinase Cbeta2 prevents acute effects of high glucose on vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation (2004) 1.88
Gene silencing of the mitochondrial adaptor p66(Shc) suppresses vascular hyperglycemic memory in diabetes. Circ Res (2012) 1.85
Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Hypertension (2006) 1.80
Deletion of p66shc gene protects against age-related endothelial dysfunction. Circulation (2004) 1.69
Genetic deletion of p66(Shc) adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress. Proc Natl Acad Sci U S A (2007) 1.63
Assessment of flow-mediated dilation reproducibility: a nationwide multicenter study. J Hypertens (2012) 1.62
Circulating biomarkers with preventive, diagnostic and prognostic implications in cardiovascular diseases. Int J Cardiol (2011) 1.62
Mammalian target of rapamycin signaling in cardiac physiology and disease. Circ Res (2014) 1.59
Rheb is a critical regulator of autophagy during myocardial ischemia: pathophysiological implications in obesity and metabolic syndrome. Circulation (2012) 1.56
Genetic polymorphism of the renin-angiotensin-aldosterone system and arterial hypertension in the Italian population: the GENIPER Project. J Hypertens (2003) 1.52
Cardiovascular health in migrants: current status and issues for prevention. A collaborative multidisciplinary task force report. J Cardiovasc Med (Hagerstown) (2014) 1.50
Do diabetes, metabolic syndrome or their association equally affect biventricular function? A tissue Doppler study. Hypertens Res (2012) 1.49
Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. Blood Press (2005) 1.49
Left bundle-branch block--pathophysiology, prognosis, and clinical management. Clin Cardiol (2007) 1.48
Nitric-oxide-mediated relaxations in salt-induced hypertension: effect of chronic beta1 -selective receptor blockade. J Hypertens (2002) 1.47
Functional cross-talk between angiotensin II and epidermal growth factor receptors in NIH3T3 fibroblasts. J Hypertens (2002) 1.46
Hypertension guidelines: criteria that might make them more clinically useful. Am J Hypertens (2002) 1.45
Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. Am J Hypertens (2008) 1.44
High prevalence and poor control of hypertension in primary care: cross-sectional study. J Hypertens (2004) 1.43
Rethinking targets of blood pressure and guidelines for hypertension clinical management. Nephrol Dial Transplant (2010) 1.42
Drug interactions with angiotensin receptor blockers. Expert Opin Drug Saf (2005) 1.41
Stem cell and progenitor cell therapy in peripheral artery disease. A critical appraisal. Thromb Haemost (2010) 1.41
Altered regulation of endothelin A receptor subtype in the cerebral arterioles in response to a Japanese-style diet, in stroke-prone hypertensive rats. J Hypertens (2003) 1.41
The management of the type 2 diabetic patient with hypertension - too late and too little: suggested improvements. Blood Press (2008) 1.40
Lack of protective role of HDL-C in patients with coronary artery disease undergoing elective coronary artery bypass grafting. Eur Heart J (2013) 1.40
[Hypertensive heart disease: diagnostic and therapeutic guidelines]. G Ital Cardiol (Rome) (2008) 1.39
Olmesartan-based therapies: an effective way to improve blood pressure control and cardiovascular protection. J Hypertens (2013) 1.39
Antihypertensive efficacy of olmesartan medoxomil and ramipril in elderly patients with mild to moderate hypertension grouped according to renal function status : a retrospective analysis. High Blood Press Cardiovasc Prev (2013) 1.39
The Pl(A1/A2) polymorphism of glycoprotein IIIa and cerebrovascular events in hypertension: increased risk of ischemic stroke in high-risk patients. J Hypertens (2007) 1.35
Treatment of peripheral arterial disease using stem and progenitor cell therapy. J Vasc Surg (2010) 1.32
Arterial stiffness as an independent predictor of longitudinal changes in cognitive function in the older individual. J Hypertens (2007) 1.32
Atrial natriuretic peptide gene polymorphisms and risk of ischemic stroke in humans. Stroke (2004) 1.22
Abdominal obesity is associated with microalbuminuria and an elevated cardiovascular risk profile in patients with hypertension. Vasc Health Risk Manag (2009) 1.22
Impact of 4 different definitions used for the assessment of the prevalence of the Metabolic Syndrome in primary healthcare: The German Metabolic and Cardiovascular Risk Project (GEMCAS). Cardiovasc Diabetol (2007) 1.22
Arterial stiffness is an independent risk factor for cognitive impairment in the elderly: a pilot study. J Hypertens (2005) 1.22
Insulin-like growth factor-1 as a vascular protective factor. Circulation (2004) 1.21
Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials. Am J Hypertens (2011) 1.21
A global perspective on blood pressure treatment and control in a referred cohort of hypertensive patients. J Clin Hypertens (Greenwich) (2010) 1.18
Low-grade albuminuria and cardiovascular risk : what is the evidence? Clin Res Cardiol (2007) 1.16
Dyslipidemia in primary care--prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS). Cardiovasc Diabetol (2008) 1.14
Prevalence of obesity in primary care using different anthropometric measures--results of the German Metabolic and Cardiovascular Risk Project (GEMCAS). BMC Public Health (2008) 1.13
Final common molecular pathways of aging and cardiovascular disease: role of the p66Shc protein. Arterioscler Thromb Vasc Biol (2007) 1.11
Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol (2007) 1.10
Age- and sex-specific prevalence and ten-year risk for cardiovascular disease of all 16 risk factor combinations of the metabolic syndrome - A cross-sectional study. Cardiovasc Diabetol (2010) 1.09
Right ventricular dysfunction in patients with end-stage renal disease. Am J Nephrol (2010) 1.08
Influence of rs5065 atrial natriuretic peptide gene variant on coronary artery disease. J Am Coll Cardiol (2012) 1.07
Chronic kidney disease in hypertension under specialist care: the I-DEMAND study. J Hypertens (2010) 1.07
Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction. Clin Sci (Lond) (2009) 1.06
Regional differences in the prevalence of the metabolic syndrome in primary care practices in Germany. Dtsch Arztebl Int (2008) 1.06
Biomarkers: optimizing treatment guidance in heart failure. Clin Res Cardiol (2011) 1.05
Incidence and predictors of hypoglycaemia in type 2 diabetes - an analysis of the prospective DiaRegis registry. BMC Endocr Disord (2012) 1.05
Effect of thiazide on renal gene expression of apical calcium channels and calbindins. Am J Physiol Renal Physiol (2004) 1.04
Blood pressure control in Italy: analysis of clinical data from 2005-2011 surveys on hypertension. J Hypertens (2012) 1.04
Vascular inflammation and endothelial dysfunction in experimental hypertension. Int J Hypertens (2011) 1.03
Transcatheter closure of post-myocardial infarction ventricular septal rupture. Circ Cardiovasc Interv (2013) 1.02
Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer (2008) 1.02
Overweight, obesity and high waist circumference: regional differences in prevalence in primary medical care. Dtsch Arztebl Int (2008) 1.00
Population-level changes to promote cardiovascular health. Eur J Prev Cardiol (2012) 1.00
Deletion of the activated protein-1 transcription factor JunD induces oxidative stress and accelerates age-related endothelial dysfunction. Circulation (2013) 0.99
Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia). Diabetes Metab Res Rev (2014) 0.99
Cost-effectiveness of the artificial liver support system MARS in patients with acute-on-chronic liver failure. Eur J Gastroenterol Hepatol (2010) 0.98
Tumor necrosis factor-alpha as trigger of platelet activation in patients with heart failure. Blood (2005) 0.98
Markers of inflammation and fibrosis are related to cardiovascular damage in hypertensive patients with metabolic syndrome. Am J Hypertens (2007) 0.98
Antiplatelet/anticoagulant agents and chronic subdural hematoma in the elderly. PLoS One (2013) 0.98
Cardiac implications of hypoglycaemia in patients with diabetes - a systematic review. Cardiovasc Diabetol (2013) 0.97
Phosphodiesterase 4D and 5-lipoxygenase activating protein genes and risk of ischemic stroke in Sardinians. Eur J Hum Genet (2009) 0.97
Clinical impact of a new left bundle branch block following TAVI implantation: 1-year results of the TAVIK cohort. Clin Res Cardiol (2014) 0.97
Acute atrial tachyarrhythmia induces angiotensin II type 1 receptor-mediated oxidative stress and microvascular flow abnormalities in the ventricles. Eur Heart J (2009) 0.96
C2238 atrial natriuretic peptide molecular variant is associated with endothelial damage and dysfunction through natriuretic peptide receptor C signaling. Circ Res (2013) 0.95
MELD-XI score and cardiac mortality or transplantation in patients after Fontan surgery. Heart (2013) 0.95
Angiotensin II type 2 receptors contribute to vascular responses in spontaneously hypertensive rats treated with angiotensin II type 1 receptor antagonists. Am J Hypertens (2005) 0.95
IGF-1 and atherothrombosis: relevance to pathophysiology and therapy. Clin Sci (Lond) (2011) 0.95
Hypoglycaemia is more frequent in type 2 diabetic patients with co-morbid vascular disease: an analysis of the DiaRegis registry. Eur J Prev Cardiol (2011) 0.94
Increased temporal dispersion of myocardial repolarization in myotonic dystrophy type 1: beyond the cardiac conduction system. Int J Cardiol (2010) 0.94
Predictors of complications in therapeutic plasma exchange. J Clin Apher (2009) 0.94
Association of heart rate with microalbuminuria in cardiovascular risk patients: data from I-SEARCH. J Hypertens (2008) 0.94
Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the i-SEARCH global study. J Hypertens (2007) 0.94
Left ventricular mass increase is associated with cognitive decline and dementia in the elderly independently of blood pressure. Eur Heart J (2009) 0.94
NPR-C: a component of the natriuretic peptide family with implications in human diseases. J Mol Med (Berl) (2010) 0.93
Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy. Vasc Health Risk Manag (2007) 0.93
Gene polymorphisms of the renin-angiotensin-aldosterone system and the risk of ischemic stroke: a role of the A1166C/AT1 gene variant. J Hypertens (2004) 0.93
Restoring the dysfunctional endothelium. Curr Pharm Des (2007) 0.93
Blood pressure management in a cohort of hypertensive patients in Germany treated by cardiologists. Clin Res Cardiol (2011) 0.93
Development of heart failure in recent hypertension trials. J Hypertens (2008) 0.92
Enhanced TNF alpha and oxidative stress in patients with heart failure: effect of TNF alpha on platelet O2- production. Thromb Haemost (2003) 0.91
Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes. Cardiovasc Diabetol (2014) 0.91